{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:58:58Z","timestamp":1790150338860,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100011928","name":"Swiss Group for Clinical Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Institute for Health Research (NIHR) UCLH Clinical Research Facility"},{"name":"Cancer Research UK Experimental Cancer Medicine Centre"},{"name":"UCL\/UCLH Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejca.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T07:25:03Z","timestamp":1523604303000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-8080","authenticated-orcid":false,"given":"Andreas","family":"Wicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Xyrafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Hawle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Cmiljanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cmiljanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dimitrijevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pr\u00eatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Ritschard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-6287","authenticated-orcid":false,"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.03.012_bib1","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2018.03.012_bib2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.012_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1874312901206010245","article-title":"The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases","volume":"6","author":"Banham-Hall","year":"2012","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.ejca.2018.03.012_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances","volume":"442","author":"So","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.ejca.2018.03.012_bib5","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1074\/jbc.M112.379446","article-title":"Selective inhibition of phosphoinositide 3-kinase p110\u03b1 preserves lymphocyte function","volume":"288","author":"So","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2018.03.012_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2018.03.012_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1741-7015-10-161","article-title":"Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment","volume":"10","author":"Brana","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2018.03.012_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.012_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2018.03.012_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.03.012_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/1471-2407-13-549","article-title":"Identification of the IGF1\/PI3K\/NF \u03baB\/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer","volume":"13","author":"Koti","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2018.03.012_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-13-1070","article-title":"Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy","volume":"20","author":"Saura","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.012_bib13","unstructured":"Baselga J, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, et\u00a0al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+\/HER2\u2013advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. In: Present San Antonio Breast Cancer Symp Dec 8\u201312, 2015; San Antonio, TX, USA Abstr S6\u2013S01."},{"key":"10.1016\/j.ejca.2018.03.012_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.celrep.2013.12.035","article-title":"Assessing PIK3CA and PTEN in early-phase trials with PI3K\/AKT\/mTOR inhibitors","volume":"6","author":"Janku","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2018.03.012_bib15","series-title":"European medicines agency - find medicine - zydelig","author":"EMA","year":"2016"},{"key":"10.1016\/j.ejca.2018.03.012_bib16","series-title":"Approved drugs > idelalisib","author":"FDA","year":"2015"},{"key":"10.1016\/j.ejca.2018.03.012_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00129785-200505020-00003","article-title":"Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases","volume":"5","author":"van der Kuip","year":"2005","journal-title":"Am J PharmacoGenomics"},{"key":"10.1016\/j.ejca.2018.03.012_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2011.546344","article-title":"Mechanisms of drug resistance in kinases","volume":"20","author":"Barouch-Bentov","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejca.2018.03.012_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors","volume":"3","author":"Daub","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2018.03.012_bib20","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/blood.V126.23.3707.3707","article-title":"Up-regulation of the PI3K signaling pathway Mediates resistance to idelalisib","volume":"126","author":"Meadows","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2018.03.012_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2018.03.012_bib22","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, Pan-Class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2018.03.012_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2652","article-title":"Abstract 2652: pre-clinical activity and mechanism of action of the novel dual PI3K\/mTOR inhibitor PQR309 in B-cell lymphomas","author":"Tarantelli","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.012_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2664","article-title":"Abstract 2664: PQR309: structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K\/mTOR inhibitor","author":"Cmiljanovic","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.012_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-4514","article-title":"Abstract 4514: PQR309: a potent, brain-penetrant, dual pan-PI3K\/mTOR inhibitor with excellent oral bioavailability and tolerability","author":"Cmiljanovic","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.012_bib26","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2018.03.012_bib27","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","author":"Tarantelli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.012_bib28","article-title":"BELLE-3: a Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment","author":"Di Leo","year":"2016","journal-title":"San Antonio Breast Cancer Symp"},{"key":"10.1016\/j.ejca.2018.03.012_bib29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/2159-8290.CD-14-0971","article-title":"RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1\/2 inhibitors","volume":"5","author":"Cheng","year":"2015","journal-title":"Canc Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T15:02:30Z","timestamp":1571151750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918307305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"alternative-id":["S0959804918307305"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}